

Attorney Docket No.: DEX0499US.NP
Inventors: Fan et al.
Serial No.: 10/593,799
Filing Date: August 6, 2007
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): An antibody produced by a hybridoma of American Type Culture Collection accession number PTA-5878, PTA-5879, PTA-6146, PTA-6147 and PTA-6629 or which competes for binding to a same epitope as the epitope bound by the antibody produced by a hybridoma of American Type Culture Collection accession number PTA-5878, PTA-5879, PTA-6146, PTA-6147 and PTA-6629, wherein said competing antibody specifically binds Lng105 and Lng105 comprises amino acids 20-413 of SEQ ID NO:1 or amino acids 26-421 of SEQ ID NO:2.

Claim 2 (previously presented): The antibody of claim 1 which is a monoclonal antibody, an antibody fragment of a chimeric or humanized antibody.

Claims 3-4 (canceled)

Claim 5 (original): The antibody of claim 1 which is produced by immunization with Lng105 protein.

Claim 6 (original): The antibody of claim 1 which binds to native Lng105 protein.

Claim 7 (canceled)

Attorney Docket No.: **DEX0499US.NP**
Inventors: **Fan et al.**
Serial No.: **10/593,799**
Filing Date: **August 6, 2007**
Page 3

Claim 8 (previously presented): The antibody of claim 1 further comprising a growth inhibitory agent, an imaging agent or a cytotoxic agent conjugated thereto.

Claims 9-10 (canceled)

Claim 11 (previously presented): The antibody of claim 8 wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

Claim 12 (canceled)

Claim 13 (previously presented): The antibody of claim 11, wherein the toxin is selected from the group consisting of a ricin, saponin, maytansinoid and calicheamicin.

Claim 14 (canceled)

Claim 15 (original): The antibody of claim 1 that selectively binds Lng105 in a bodily fluid.

Claim 16 (original): The antibody of claim 1 that selectively binds a Lng105-expressing cell.

Claim 17 (original): The antibody of claim 1 that inhibits the growth of a Lng105-expressing cell.

Claims 18-20 (canceled)

Attorney Docket No.: **DEX0499US.NP**
Inventors: **Fan et al.**
Serial No.: **10/593,799**
Filing Date: **August 6, 2007**
Page 4

Claim 21 (original): The antibody of claim 16, wherein the Lng105-expressing cell is a cancer cell.

Claim 22 (original): The antibody of claim 21, wherein the cancer cell is from a cancer comprising lung or breast cancer.

Claims 23-26 (canceled)

Claim 27 (previously presented): A composition comprising the antibody of claim 1, and a carrier.

Claim 28 (previously presented): The composition of claim 27, wherein the antibody is conjugated to an imaging agent or a cytotoxic agent.

Claim 29 (canceled)

Claim 30 (original): The composition of claim 28, wherein the cytotoxic agent is a ricin, saponin, maytansinoid and calicheamicin.

Claims 31-49 (canceled)

Claim 50 (original): An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of claim 1.

Claim 51 (original): The article of manufacture of claim 50 further comprising a package insert indicating that the

Attorney Docket No.: **DEX0499US.NP**
Inventors: **Fan et al.**
Serial No.: **10/593,799**
Filing Date: **August 6, 2007**
Page 5

composition can be used to diagnose, image or treat lung or breast cancer.

Claims 52-76 (canceled)

Claim 77 (new): An antibody produced by a hybridoma of American Type Culture Collection accession number PTA-5878, PTA-5879, PTA-6146, PTA-6147 and PTA-6629.